Trial Profile

A Double-Blind, Randomized, Multiple Dose Study of Weight Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ulotaront (Primary) ; Aripiprazole; Olanzapine; Quetiapine; Risperidone
Indications Schizophrenia
Focus Therapeutic Use
Sponsors Sumitomo Pharma America; Sunovion Pharmaceuticals

28 Mar 2024 Status changed from recruiting to completed.
08 Dec 2023 Planned End Date changed from 23 Oct 2023 to 29 Mar 2024.
08 Dec 2023 Planned primary completion date changed from 23 Oct 2023 to 29 Mar 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com